Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05391113
Recruiting Not applicable

REward SYSTem in Autism Spectrum Disorder and Addictive Disorder

NCT05391113 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Tours
Phase
Not applicable
Started
2023-07-27
Last updated
2024-12-06

Condition(s) studied

Autism Spectrum Disorder

Investigational drug(s) / intervention(s)

MRIEEG

MRI: an fMRI measurement of the BOLD physiological signal for sensory responses

EEG: These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.

Study summary

An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Arm A ˗ Concerning ASD patients: Adult carrying the diagnosis of ASD (DSM-5, ADOS, ADI-R criteria) Arm B ˗ Concerning FAD patients: Adult diagnosed with FA presenting with food addiction (DSM-5, YFAS 2.0, BES \>= 18 criteria). Arm C ˗ Concerning healthy volunteers : Adult with no neurological and psychiatric history , absence of progressive somatic pathologies or with vital risk. For all participants: * Age greater than or equal to 18 years old * Without intellectual delay (IQ \> 70). * Able to understand and apply the instruction when an active task is proposed, according to the estimate of the investigator. * Free, express, informed and written consent of the participant. * Participant affiliated to a social security scheme Exclusion Criteria: * Neuromotor disorders. * Visual disturbances not corrected or incompatible with MRI. * Known epilepsy. * Current substance use disorder with emotional distress/significant impact on functional outcome * Rare genetic syndrome. * Contraindications to MRI (other than body circumference) * For women of childbearing age: negative urine or blood pregnancy test * Person subject to a measure of judicial protection (safeguard of justice, curatorship, guardianship or family authorization)

Primary outcome measure(s)

  • Blood Oxygene Level Dependent (BOLD) MRI signal — At inclusion
    Measurement in fMRI of the BOLD signal for each condition (interest, addiction, social) will be carried out in order to highlight the possible alterations of the reward system, in particular at the level of the striatum in terms of cerebral activation for each of the groups of subjects. (FAD, ASD and HV).

Trial sites (3)

FacilityCityRegionStatus
Center-Val de Loire Region Autism Resource Center Tours France Recruiting
University Addictology Service, Liaison Team and Addictology Care Tours France Recruiting
University Hospital, Medical Imaging Service Tours France Recruiting

More University Hospital, Tours trials in France

Colorectal Cancer Screnning Colonoscopy Under Hypnosis Recruiting
Development, Standardisation and Standardisation Project for a New Memory Assessment Recruiting
Methoxyflurane Versus Usual Care for Non-Traumatic Pain in Emergency Departments Starting soon
Communication Enhancement Among Ventilated Patients in Intensive Care Recruiting
Impact on Delirium of the Use of DEXmedetomidine as First-line Sedation in PEDIAtric Intensive Care Starting soon

Other trials for the same condition

Study of the Genetic Factors Involved in Autism and Related Disorders Recruiting
MRI Study of Subjects with ASD, Their Relatives and TD Recruiting
Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents Active, not recruiting
Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders Recruiting
Understanding the Mechanisms of Autism : an MRI and Social Cognition Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05391113 on ClinicalTrials.gov ↗ ← All trials in France